Background: COVID-19 has been one of the worst pandemics that hit the humans. Mucormycosis in people with COVID-19 have been increasingly reported world-wide, in particular from India. Rhino-Orbito-Cerebral Mucormycosis is the most common form of it. Intracranial involvement of mucormycosis increased the fatality rate to as high as 90%. Aim and Objectives: To assess the clinical manifestations of the patients with post COVID19 mucormycosis and to study steroids and oxygen usage in such patients. Materials and Method: This retrospective cross-sectional study was carried out in the Department of Ear, Nose and Throat, Grant medical college and Sir JJ Group of Hospitals, Mumbai, from Oct 2020 to September 2022. Observation and Results: This study included 163 patients among which 115 were male (71%) and 48 females (29%) and also it was observed that maximum patients were in the age group of 41-60yrs (60%). 55% presented with symptoms in less than 10 days of COVID-19 infection. 71% had history of diabetes. 63% had received steroids treatment, while 41% required oxygen during COVID-19. 80% patients had nose related complaints, while 36% had throat related complaints and in other complaints 39% and 22% of the patients had facial pain and proptosis observed in major. Conclusion: COVID-19 infection are more susceptible to mucormycosis and to ascertain the relationships between the present treatment protocol, prospective co-morbidities, and environmental variables and mucormycosis infection, more study is needed.